Reata Pharmaceuticals (Columbia) Completes $78 Million Equity Financing for Second Pivotal Trial of Bardoxolone Methyl (7/14/2010)

Reata Pharmaceuticals is a Columbia University spinoff focused on pharmaceuticals for intractable diseases.

Reata Pharmaceuticals, Inc. (“Reata”) has completed a $78 million equity financing led by existing investors CPMG, Inc. and Novo A/S. This financing brings the total raised by the Company to $180 million since inception. [read more]

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


%d bloggers like this: